A review of clinical pharmacology deficiencies of European centralised drug marketing authorisation applications

被引:2
作者
Hay, Justin L. [1 ,3 ]
O'Sullivan, Jane [2 ]
Kerwash, Essam [1 ,3 ]
Ilie, Alexandra-Roxana [4 ]
Cole, Susan M. [1 ,3 ,5 ]
机构
[1] Med & Healthcare Prod Regulatory Agcy, London, England
[2] European Med Agcy, London, England
[3] EMA Modelling & Simulat Working Grp, London, England
[4] Univ Coll Cork, Cork, Ireland
[5] EMA Pharmacokinet Working Party, London, England
基金
欧盟地平线“2020”;
关键词
Clinical pharmacology; Pharmacokinetics; Pharmacodynamics; Major objections; Drug development; Regulatory;
D O I
10.1016/j.yrtph.2020.104804
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
The aim of this observational review was to review trends in deficiencies in clinical pharmacology dossiers by analysing the frequency and characteristics of major objections (MOs) related to clinical pharmacokinetics and dose-exposure-response (DER) relationships in assessment reports for medicinal products submitted in centralised procedures to the European Medicines Agency (EMA). Initial Assessor (Day 120) assessment reports between 2013 and 2018 were reviewed MOs and characterised with regards to ATC code, orphan status, legal basis and type of molecule, major objection topic and if scientific advice had been sought during development. 23% of the 551 identified Day 120 assessments contained at least one major objection related to clinical pharmacology. Most common topics identified were related to the pharmacokinetics in the target populations, analytical methods, dose-exposure-response relationships, absorption, distribution, metabolism, excretion, comparative bioavailability, and bioequivalence issues. The importance of a robust clinical PK dossier in the assessment of marketing authorisation applications was highlighted by the high frequency of major objections. This review should provide valuable insights to ensure that aspects of bioanalytical methods, comparative bioavailability, PK in the target population and DER relationships are thoroughly addressed in future marketing authorisation applications.
引用
收藏
页数:5
相关论文
共 15 条
[1]   Regulatory issues for orphan medicines: A review [J].
Bouwman, Maria Luisa ;
Simoes Sousa, Joao Jose ;
Tavares Pina, Maria Eugenia .
HEALTH POLICY AND TECHNOLOGY, 2020, 9 (01) :115-121
[2]   An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe [J].
Ebbers, Hans C. ;
Langedijk, Joris ;
Bouvy, Jacoline C. ;
Hoekman, Jarno ;
Boon, Wouter P. C. ;
de Jong, Jean Philippe ;
De Bruin, Marie L. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (10) :1237-1244
[3]  
European Medicines Agency, 2009, EMEAMB307542009
[4]  
European Medicines Agency, 2018, GUID EV MED PROD IND
[5]  
European Medicines Agency, 2019, MOD SIM WORK PART
[6]  
European Medicines Agency, 2018, EUR MED AG ANN REP
[7]  
European Medicines Agency, 2020, ORPH MED EU
[8]   REGULATORY WATCH Impact of scientific advice from the European Medicines Agency [J].
Hofer, Matthias P. ;
Jakobsson, Christina ;
Zafiropoulos, Nikolaos ;
Vamvakas, Spiros ;
Vetter, Thorsten ;
Regnstrom, Jan ;
Hemmings, Robert J. .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (05) :302-U17
[9]  
Metlay JP, 2006, EMERG INFECT DIS, V12, P183
[10]  
Musuamba FT, 2017, CPT-PHARMACOMET SYST, V6, P418, DOI 10.1002/psp4.12196